{
  "title": "IgA Vasculitis (HSP) with Rapidly Progressive Glomerulonephritis in the Elderly",
  "type": "case-presentation",
  "created": "2025-11-27",
  "author": "SZMC Geriatrics Department",
  "theme": "navy-gold",
  "slides": [
    {
      "id": "slide-001",
      "type": "title",
      "order": 0,
      "data": {
        "title": "IgA Vasculitis (Henoch-Schönlein Purpura) with RPGN",
        "subtitle": "A Diagnostic Odyssey in a 78-Year-Old with Respiratory Compromise",
        "presenter": "SZMC Geriatrics Department",
        "date": "November 2025"
      }
    },
    {
      "id": "slide-002",
      "type": "toc",
      "order": 1,
      "data": {}
    },
    {
      "id": "slide-003",
      "type": "section-header",
      "order": 2,
      "data": {
        "sectionTitle": "Patient Profile: The Vulnerable Host",
        "sectionNumber": "1"
      }
    },
    {
      "id": "slide-004",
      "type": "two-column",
      "order": 3,
      "data": {
        "title": "Patient Profile: Mr. Eli Ohayon, 78M",
        "leftColumn": "<div class='callout callout-info'><div class='callout-content'><i class='fas fa-user'></i> <strong>DOB:</strong> 25/08/1947</div></div><h4><i class='fas fa-lungs'></i> Respiratory Phenotype</h4><ul><li><strong>Bronchiectasis</strong> – chronic</li><li><strong>Steroid-dependent asthma</strong></li><li><strong>Chronic sinusitis</strong> (post-FESS)</li><li><strong>Occupational:</strong> Turpentine exposure</li></ul><h4><i class='fas fa-hospital'></i> 4+ Admissions (2018-2023)</h4><p>All respiratory exacerbations<br>Treated with IV abx + steroids</p>",
        "rightColumn": "<div class='callout callout-warning'><div class='callout-content'><i class='fas fa-kidneys'></i> <strong>KEY POINT</strong></div></div><h4>Baseline Creatinine: STABLE</h4><p style='font-size:1.5rem;text-align:center;color:var(--success);font-weight:700;'>1.1-1.2 mg/dL</p><p style='text-align:center;'>Despite multiple septic insults,<br>aminoglycoside & contrast exposures</p><div class='callout callout-info'><div class='callout-content'>This is why the <strong>acute rise</strong> in October 2025 was so alarming!</div></div>"
      }
    },
    {
      "id": "slide-005",
      "type": "statistics-visual",
      "order": 4,
      "data": {
        "stat1Value": "78",
        "stat1Label": "Age (Years)",
        "stat1Sub": "High-risk population",
        "stat2Value": "1.1-1.2",
        "stat2Label": "Baseline Creatinine",
        "stat2Sub": "mg/dL (Stable for years)",
        "stat3Value": "4+",
        "stat3Label": "Prior Admissions",
        "stat3Sub": "Respiratory exacerbations",
        "stat4Value": "651",
        "stat4Label": "Serum IgA",
        "stat4Sub": "mg/dL (Normal: 70-400)",
        "statsCitations": "Patient historical data 2018-2025"
      }
    },
    {
      "id": "slide-006",
      "type": "section-header",
      "order": 5,
      "data": {
        "sectionTitle": "Act I: The Trigger Event (October 2025)",
        "sectionNumber": "2"
      }
    },
    {
      "id": "slide-007",
      "type": "two-column",
      "order": 6,
      "data": {
        "title": "The Trigger: October 2025",
        "leftColumn": "<div class='callout callout-warning'><div class='callout-title'><i class='fas fa-lungs-virus'></i> Mid-October</div><div class='callout-content'>Respiratory infection → Cephalosporins</div></div><h4>Treatment Given</h4><ul><li>Cefuroxime (Zinnat)</li><li>Ceftriaxone (Rocephin)</li></ul><p><i class='fas fa-check' style='color:var(--success);'></i> Infection cleared</p><h4><i class='fas fa-calendar'></i> Oct 29 – ER Visit</h4><div class='callout callout-danger'><div class='callout-content'><strong>NEW:</strong> Purpuric rash on legs</div></div>",
        "rightColumn": "<h4><i class='fas fa-stethoscope'></i> Initial Assessment</h4><table class='medications-table'><thead><tr><th>Finding</th><th>Value</th></tr></thead><tbody><tr><td><i class='fas fa-disease'></i> Rash</td><td><strong>Palpable purpura</strong></td></tr><tr><td><i class='fas fa-kidneys'></i> Creatinine</td><td style='color:var(--success);'><strong>1.21</strong> mg/dL ✓</td></tr><tr><td><i class='fas fa-tint'></i> UA</td><td style='color:var(--warning);'><strong>Microhematuria</strong> ⚠</td></tr></tbody></table><div class='callout callout-info' style='margin-top:12px;'><div class='callout-content'><i class='fas fa-lightbulb'></i> Microhematuria = <strong>early warning</strong> of renal involvement!</div></div>"
      }
    },
    {
      "id": "slide-008",
      "type": "two-column",
      "order": 7,
      "data": {
        "title": "The Missed Signal: Oct 30 HSP Diagnosis",
        "leftColumn": "<div class='callout callout-info'><div class='callout-title'><i class='fas fa-diagnoses'></i> Diagnosis</div><div class='callout-content'><strong>HSP (IgA Vasculitis)</strong></div></div><h4>Clinical Features</h4><ul><li><i class='fas fa-check' style='color:var(--success);'></i> Palpable purpura (legs)</li><li><i class='fas fa-times' style='color:var(--muted);'></i> No joint pain</li><li><i class='fas fa-times' style='color:var(--muted);'></i> No abdominal pain</li><li><i class='fas fa-check' style='color:var(--success);'></i> Cr preserved</li></ul><h4>Discharge Plan</h4><p><strong>Prednisone 20mg</strong> daily + f/u</p>",
        "rightColumn": "<div class='callout callout-danger'><div class='callout-title'><i class='fas fa-exclamation-triangle'></i> MISSED</div><div class='callout-content'><strong>Microhematuria</strong> present!<br>= Early renal involvement</div></div><h4>The Problem</h4><ul><li>20mg OK for <strong>cutaneous</strong> HSP</li><li>But <strong>insufficient</strong> for renal HSP</li></ul><h4>Should Have Done</h4><ul><li><i class='fas fa-pills'></i> Steroids 1mg/kg</li><li><i class='fas fa-user-md'></i> Nephro referral</li><li><i class='fas fa-vials'></i> Serial Cr monitoring</li></ul>"
      }
    },
    {
      "id": "slide-009",
      "type": "section-header",
      "order": 8,
      "data": {
        "sectionTitle": "Act II: The Collapse (November 20-24, 2025)",
        "sectionNumber": "3"
      }
    },
    {
      "id": "slide-010",
      "type": "statistics-visual",
      "order": 9,
      "data": {
        "stat1Value": "1.21→2.57",
        "stat1Label": "Creatinine (mg/dL)",
        "stat1Sub": "↑112% in 3 weeks!",
        "stat2Value": "55→24",
        "stat2Label": "eGFR (mL/min)",
        "stat2Sub": "↓56% decline",
        "stat3Value": "28.89",
        "stat3Label": "CRP (mg/dL)",
        "stat3Sub": "Marked inflammation",
        "stat4Value": "3 wks",
        "stat4Label": "Time to AKI",
        "stat4Sub": "Rapid progression",
        "statsCitations": "November 20, 2025 – Admission labs showing catastrophic renal decline"
      }
    },
    {
      "id": "slide-011",
      "type": "two-column",
      "order": 10,
      "data": {
        "title": "The \"Red Herring\": UTI vs Reality",
        "leftColumn": "<h4><i class='fas fa-bacteria'></i> Initial Dx: UTI/Sepsis</h4><table class='medications-table'><thead><tr><th>Organism</th></tr></thead><tbody><tr><td><strong>Pseudomonas</strong></td></tr><tr><td><strong>Enterobacter</strong></td></tr></tbody></table><div class='callout callout-info'><div class='callout-content'><strong>Plan:</strong> Antibiotics → CRP ↓ → Cr recovers</div></div>",
        "rightColumn": "<h4><i class='fas fa-chart-line'></i> The Dissociation</h4><table class='medications-table'><thead><tr><th>Date</th><th>CRP</th><th>Cr</th></tr></thead><tbody><tr><td>Nov 20</td><td>28.89</td><td>2.57</td></tr><tr><td>Nov 23</td><td style='color:var(--success);'>↓</td><td style='color:var(--secondary);'>2.78↑</td></tr><tr><td>Nov 24</td><td style='color:var(--success);'>5.24↓</td><td style='color:var(--secondary);'><strong>3.63↑</strong></td></tr></tbody></table><div class='callout callout-danger'><div class='callout-content'><i class='fas fa-exclamation-triangle'></i> CRP improved but<br><strong>kidneys kept failing!</strong></div></div>"
      }
    },
    {
      "id": "slide-012",
      "type": "pathophysiology",
      "order": 11,
      "data": {
        "pathTitle": "Why UTI Tx Didn't Fix the Kidneys",
        "trigger": "<strong>Two Separate Pathologies:</strong><br>1. UTI (Pseudomonas)<br>2. IgA glomerulonephritis",
        "mechanism": "• Antibiotics ✓ → CRP ↓<br>• Antibiotics ✗ → IgA damage continues<br>• Creatinine keeps rising",
        "effects": "• Glomerular inflammation<br>• Crescent formation<br>• ↓ Filtration<br>• → Fibrosis",
        "clinical": "• Cr ↑ despite infection control<br>• Active sediment (RBC casts)<br>• Oliguria",
        "geriatricFactors": "<strong>Geriatric Factors:</strong><br>• UTI unmasks underlying disease<br>• Age-related nephron loss<br>• Atypical presentations",
        "pathCitation": "Clinical correlation Nov 2025"
      }
    },
    {
      "id": "slide-013",
      "type": "section-header",
      "order": 12,
      "data": {
        "sectionTitle": "Act III: Unmasking the Enemy (Nov 25-26)",
        "sectionNumber": "4"
      }
    },
    {
      "id": "slide-014",
      "type": "key-points-visual",
      "order": 13,
      "data": {
        "kpTitle": "Diagnostic Pivot: The Active Sediment",
        "kp1": "<strong>Protein 874 mg/24h</strong><br>Significant proteinuria – approaching nephrotic range",
        "kp2": "<strong>CrCl 15.6 mL/min</strong><br>Severely reduced GFR (CKD Stage 4-5)",
        "kp3": "<strong>Heavy Blood in UA</strong><br>Glomerular source bleeding",
        "kp4": "<strong>Heavy Protein in UA</strong><br>Active glomerular damage",
        "kp5": "<strong>RBC CASTS</strong><br><em>Pathognomonic for GN!</em><br>Not UTI – this is glomerular disease",
        "kp6": "<strong>Clinical Pearl</strong><br>RBC casts = active glomerular bleeding trapped in protein matrix"
      }
    },
    {
      "id": "slide-015",
      "type": "two-column",
      "order": 14,
      "data": {
        "title": "Serology: The Smoking Gun",
        "leftColumn": "<h4><i class='fas fa-check-circle' style='color:var(--success);'></i> POSITIVE</h4><table class='medications-table'><tbody><tr class='med-beers'><td><strong>IgA</strong></td><td><strong style='color:var(--secondary);'>651</strong></td><td>↑↑</td></tr><tr><td>IgE</td><td>308</td><td>↑ (atopy)</td></tr></tbody></table><div class='callout callout-danger' style='margin-top:12px;'><div class='callout-content'><strong>IgA 651 mg/dL</strong><br>(Normal: 70-400)<br>= IgA Vasculitis!</div></div>",
        "rightColumn": "<h4><i class='fas fa-times-circle' style='color:var(--success);'></i> NEGATIVE (Rules Out)</h4><table class='medications-table'><tbody><tr class='med-normal'><td>ANCA</td><td>⊖</td><td>No GPA/MPA</td></tr><tr class='med-normal'><td>ANA</td><td>⊖</td><td>No Lupus</td></tr><tr class='med-normal'><td>C3/C4</td><td>Normal</td><td>No PSGN</td></tr><tr class='med-normal'><td>Anti-GBM</td><td>⊖</td><td>No Goodpasture</td></tr></tbody></table><div class='callout callout-info' style='margin-top:12px;'><div class='callout-content'><strong>Dx: HSP Nephritis</strong><br>→ RPGN</div></div>"
      }
    },
    {
      "id": "slide-016",
      "type": "algorithm",
      "order": 15,
      "data": {
        "algoTitle": "RPGN Diagnostic Algorithm",
        "algoStart": "AKI + Active Sediment<br>(Protein + Blood + RBC Casts)",
        "algoDecision": "Check: ANCA, ANA, Anti-GBM, C3/C4, IgA",
        "algoYes": "<strong>ANCA+:</strong> GPA, MPA, EGPA<br><strong>Anti-GBM+:</strong> Goodpasture<br><strong>Low C3/C4:</strong> PSGN, Lupus",
        "algoNo": "<strong>All ⊖ + IgA ↑:</strong><br>HSP/IgAN ✓<br><strong>All ⊖ + IgA nl:</strong><br>Pauci-immune",
        "algoEnd": "<strong>Mr. Ohayon:</strong> ANCA⊖ ANA⊖ GBM⊖ C3/C4 nl IgA↑↑ + Purpura = <strong>HSP Nephritis</strong>",
        "algoCitation": "KDIGO GN Guidelines"
      }
    },
    {
      "id": "slide-017",
      "type": "two-column",
      "order": 16,
      "data": {
        "title": "CT Chest: Pulmonary-Renal Syndrome?",
        "leftColumn": "<div class='callout callout-warning'><div class='callout-title'><i class='fas fa-x-ray'></i> Nov 27 CT Chest</div><div class='callout-content'><strong>Ground Glass Opacities</strong><br>? Alveolar hemorrhage</div></div><h4>Differential</h4><table class='medications-table'><tbody><tr class='med-normal'><td>HSP pulmonary</td><td style='color:var(--success);'><strong>Most Likely</strong></td></tr><tr><td>DAH</td><td>Possible</td></tr><tr><td>Infection</td><td>Possible</td></tr><tr class='med-beers'><td>Goodpasture</td><td style='color:var(--secondary);'>Ruled out</td></tr></tbody></table>",
        "rightColumn": "<div class='callout callout-danger'><div class='callout-title'><i class='fas fa-lungs'></i> Pulmonary-Renal Syndrome</div><div class='callout-content'>Ground glass + RPGN = PRS</div></div><h4>Classic Triad</h4><ul><li><i class='fas fa-tint' style='color:var(--secondary);'></i> Hemoptysis</li><li><i class='fas fa-kidneys' style='color:var(--secondary);'></i> Renal failure</li><li><i class='fas fa-disease' style='color:var(--secondary);'></i> Systemic vasculitis</li></ul><div class='callout callout-info' style='margin-top:8px;'><div class='callout-content'><i class='fas fa-info-circle'></i> HSP pulmonary: Rare but reported<br><strong>Tx:</strong> Immunosuppression</div></div>"
      }
    },
    {
      "id": "slide-018",
      "type": "section-header",
      "order": 17,
      "data": {
        "sectionTitle": "The Creatinine Trajectory: Visual Analysis",
        "sectionNumber": "5"
      }
    },
    {
      "id": "slide-019",
      "type": "timeline-visual",
      "order": 18,
      "data": {
        "timelineTitle": "Creatinine Trajectory: 1.21 → 3.63 in 26 Days",
        "time1": "Sep 30",
        "event1Title": "Baseline",
        "event1Desc": "<strong style='color:var(--success);'>Cr 1.19</strong><br>Pre-crisis stable",
        "time2": "Oct 29",
        "event2Title": "HSP Dx",
        "event2Desc": "<strong style='color:var(--warning);'>Cr 1.21</strong><br>Rash onset, microhematuria",
        "time3": "Nov 20",
        "event3Title": "Admission",
        "event3Desc": "<strong style='color:var(--secondary);'>Cr 2.57</strong><br>↑112% - AKI Stage 2",
        "time4": "Nov 24",
        "event4Title": "PEAK",
        "event4Desc": "<strong style='color:var(--secondary);'>Cr 3.63</strong><br>Classic RPGN kinetics"
      }
    },
    {
      "id": "slide-020",
      "type": "statistics-visual",
      "order": 19,
      "data": {
        "stat1Value": "15.0→10.6",
        "stat1Label": "Hemoglobin (g/dL)",
        "stat1Sub": "Baseline → Nadir",
        "stat2Value": "Δ4.4",
        "stat2Label": "g/dL Drop",
        "stat2Sub": "In just 3 days!",
        "stat3Value": "12.5",
        "stat3Label": "Recovery",
        "stat3Sub": "Nov 27 stabilization",
        "stat4Value": "4",
        "stat4Label": "Possible Causes",
        "stat4Sub": "ACD, ↓EPO, DAH, dilution",
        "statsCitations": "Acute anemia: inflammation + renal + possible occult pulmonary hemorrhage"
      }
    },
    {
      "id": "slide-021",
      "type": "section-header",
      "order": 20,
      "data": {
        "sectionTitle": "Act IV: The Complication (November 27)",
        "sectionNumber": "6"
      }
    },
    {
      "id": "slide-022",
      "type": "two-column",
      "order": 21,
      "data": {
        "title": "The HBV Bombshell (Nov 27)",
        "leftColumn": "<div class='callout callout-danger'><div class='callout-title'><i class='fas fa-virus'></i> SURPRISE</div><div class='callout-content'>HBsAg <strong>REACTIVE</strong></div></div><h4>HBV Panel</h4><table class='medications-table'><tbody><tr class='med-beers'><td>HBsAg</td><td><strong>+</strong></td></tr><tr><td>Anti-HBc</td><td>-</td></tr><tr><td>Anti-HBs</td><td>-</td></tr></tbody></table><p style='margin-top:8px;'><i class='fas fa-calendar'></i> AM: Kidney biopsy done<br><i class='fas fa-vial'></i> PM: HBV+ discovered</p>",
        "rightColumn": "<h4><i class='fas fa-balance-scale'></i> The Dilemma</h4><div class='callout callout-warning'><div class='callout-content'><strong>RPGN needs:</strong><br>Pulse steroids to save kidneys</div></div><p style='text-align:center;font-size:1.5rem;'>VS</p><div class='callout callout-danger'><div class='callout-content'><strong>HBV+ risk:</strong><br>Steroids → fatal HBV reactivation</div></div><p style='text-align:center;margin-top:8px;'><i class='fas fa-skull-crossbones'></i> Mortality: <strong>5-40%</strong></p>"
      }
    },
    {
      "id": "slide-023",
      "type": "two-column",
      "order": 22,
      "data": {
        "title": "The Dilemma: Steroids vs HBV Risk",
        "leftColumn": "<div class='callout callout-danger'><div class='callout-title'><i class='fas fa-kidneys'></i> Renal Emergency</div><div class='callout-content'>No Tx → ESRD in weeks</div></div><h4>Why Steroids Critical</h4><ul><li>Crescents = Inflammation</li><li>Untreated → Fibrosis</li><li>Window: Days-weeks</li></ul><h4>Standard Tx</h4><ul><li>IV SoluMedrol 1g ×3d</li><li>Oral taper</li><li>± CTX/RTX</li></ul>",
        "rightColumn": "<div class='callout callout-warning'><div class='callout-title'><i class='fas fa-liver'></i> Hepatic Risk</div><div class='callout-content'>Steroids + HBV → Fulminant hepatitis</div></div><h4>HBV Reactivation</h4><ul><li>Steroids ↓ immune</li><li>HBV replicates</li><li>Steroids stop → BOOM</li><li>Hepatocyte death</li></ul><div class='callout callout-danger' style='margin-top:8px;'><div class='callout-content'><i class='fas fa-skull-crossbones'></i> Mortality: <strong>5-40%</strong></div></div>"
      }
    },
    {
      "id": "slide-024",
      "type": "key-points-visual",
      "order": 23,
      "data": {
        "kpTitle": "Solution: Entecavir Shield Protocol",
        "kp1": "<strong>ENTECAVIR 0.5mg</strong><br>Start IMMEDIATELY<br>Before any steroids",
        "kp2": "<strong>>90% Protection</strong><br>Reduces HBV reactivation risk<br>Inhibits viral replication",
        "kp3": "<strong>Day 2-3</strong><br>If stable → Proceed<br>with pulse Solu-Medrol",
        "kp4": "<strong>Monitor LFTs</strong><br>Weekly during steroids<br>Watch for reactivation signs",
        "kp5": "<strong>Check HBV DNA</strong><br>Viral load baseline<br>Track suppression",
        "kp6": "<strong>Continue 6-12 mo</strong><br>After stopping steroids<br>Prevent late flare"
      }
    },
    {
      "id": "slide-025",
      "type": "section-header",
      "order": 24,
      "data": {
        "sectionTitle": "Differential Diagnosis: HSP vs. Churg-Strauss",
        "sectionNumber": "7"
      }
    },
    {
      "id": "slide-026",
      "type": "two-column",
      "order": 25,
      "data": {
        "title": "DDx: HSP vs Churg-Strauss (EGPA)?",
        "leftColumn": "<div class='callout callout-warning'><div class='callout-title'><i class='fas fa-question-circle'></i> FOR EGPA</div><div class='callout-content'>\"Lung Phenotype\"</div></div><h4>Supporting</h4><ul><li>✓ Severe asthma</li><li>✓ Chronic sinusitis</li><li>✓ Historic eos: 1,800</li><li>✓ Lung infiltrates</li></ul><h4>EGPA Triad</h4><ol><li>Asthma ✓</li><li>Eos ✓ (historical)</li><li>Vasculitis ✓</li></ol>",
        "rightColumn": "<div class='callout callout-info'><div class='callout-title'><i class='fas fa-check-circle'></i> FOR HSP</div><div class='callout-content'>\"Renal Phenotype\"</div></div><h4>Refuting EGPA</h4><ul><li>✗ Eos NOW: <strong>suppressed</strong></li><li>✗ ANCA: <strong>negative</strong></li><li>✓ IgA: <strong>651</strong> (HSP marker)</li><li>✓ Palpable purpura</li><li>✓ IgA nephritis pattern</li></ul><div class='callout callout-success' style='margin-top:8px;'><div class='callout-content'><strong>Verdict: HSP</strong></div></div>"
      }
    },
    {
      "id": "slide-027",
      "type": "two-column",
      "order": 26,
      "data": {
        "title": "Why Eosinophils Are Suppressed",
        "leftColumn": "<div class='callout callout-info'><div class='callout-content'><i class='fas fa-pills'></i> On <strong>Prednisone 20mg</strong> since Oct 30</div></div><h4>Steroid Effects</h4><table class='medications-table'><tbody><tr><td>Apoptosis</td><td>Rapid eos death</td></tr><tr><td>BM suppression</td><td>↓ Production</td></tr><tr><td>Sequestration</td><td>Tissue shift</td></tr></tbody></table><p style='margin-top:8px;'>Count drops <strong>within hours</strong></p>",
        "rightColumn": "<h4><i class='fas fa-lightbulb'></i> Key Differentiator</h4><div class='callout callout-warning'><div class='callout-content'><strong>Historical eos:</strong> 1,800/µL<br><em>(before steroids)</em></div></div><h4>ANCA is the key:</h4><ul><li><strong>EGPA:</strong> MPO-ANCA + (50-70%)</li><li><strong>HSP:</strong> ANCA negative ✓</li></ul><div class='callout callout-info' style='margin-top:8px;'><div class='callout-content'><i class='fas fa-graduation-cap'></i> Always check <strong>pre-steroid</strong> labs!</div></div>"
      }
    },
    {
      "id": "slide-028",
      "type": "section-header",
      "order": 27,
      "data": {
        "sectionTitle": "Current Status & Management Plan",
        "sectionNumber": "8"
      }
    },
    {
      "id": "slide-029",
      "type": "key-points-visual",
      "order": 28,
      "data": {
        "kpTitle": "Current Clinical Status (November 27, 2025)",
        "kp1": "<strong>PROVEN VASCULITIS</strong><br>Henoch-Schönlein Purpura (IgA Vasculitis) confirmed by:<br>• Palpable purpura + Elevated IgA (651) + Negative ANCA",
        "kp2": "<strong>PRESUMED CRESCENTIC GN</strong><br>Rapidly Progressive Glomerulonephritis (RPGN):<br>• Creatinine 3.63 mg/dL (from 1.21 in 26 days)<br>• Active sediment with RBC casts",
        "kp3": "<strong>ACTIVE UTI</strong><br>Pseudomonas aeruginosa + Enterobacter infection:<br>• On appropriate antibiotic therapy<br>• CRP improving (28.89 → 5.24)",
        "kp4": "<strong>HEPATITIS B POSITIVE</strong><br>HBsAg Reactive:<br>• Major complication for immunosuppression<br>• Requires antiviral prophylaxis",
        "kp5": "<strong>KIDNEY BIOPSY</strong><br>Performed November 27:<br>• Awaiting pathology results<br>• Will confirm crescents and guide therapy",
        "kp6": "<strong>RESPIRATORY DISEASE</strong><br>Underlying bronchiectasis + asthma:<br>• Ground glass opacities on CT<br>• Possible pulmonary involvement"
      }
    },
    {
      "id": "slide-030",
      "type": "algorithm",
      "order": 29,
      "data": {
        "algoTitle": "Management: RPGN + HBV+",
        "algoStart": "HSP-RPGN + HBV+<br>Cr 3.63, GFR falling",
        "algoDecision": "Safe to immunosuppress?",
        "algoYes": "<strong>1. Entecavir 0.5mg NOW</strong><br>+ HBV DNA + LFTs<br><strong>2. Day 2-3: Pulse steroids</strong><br>SoluMedrol 500-1000mg ×3<br><strong>3. If crescents: ±CTX/RTX</strong>",
        "algoNo": "<strong>No Entecavir?</strong> → Tenofovir<br><strong>Fibrosis > Active?</strong><br>→ RRT discussion",
        "algoEnd": "<strong>Goal:</strong> Salvage kidneys before fibrosis<br><strong>Urgency:</strong> Days to weeks!",
        "algoCitation": "KDIGO; AASLD HBV Guidelines"
      }
    },
    {
      "id": "slide-031",
      "type": "medications-detailed",
      "order": 30,
      "data": {
        "medTable": "<tr class='med-normal'><td colspan='5' style='background: var(--success); color: white; font-weight: 600;'><i class='fas fa-shield-virus'></i> HEPATITIS B PROPHYLAXIS</td></tr><tr class='med-normal'><td>Entecavir <span class='med-flag'>INITIATED</span></td><td>0.5mg</td><td>Daily</td><td>HBV prophylaxis</td><td>Continue throughout immunosuppression + 6-12 months after</td></tr><tr class='med-caution'><td colspan='5' style='background: var(--primary); color: white; font-weight: 600;'><i class='fas fa-syringe'></i> IMMUNOSUPPRESSION</td></tr><tr class='med-caution'><td>IV Methylprednisolone <span class='med-flag interaction'>PENDING</span></td><td>500-1000mg</td><td>Daily × 3</td><td>RPGN rescue</td><td>Initiate after 24-48h of Entecavir</td></tr><tr class='med-caution'><td>Prednisone (oral taper)</td><td>1mg/kg</td><td>Daily → taper</td><td>Maintenance</td><td>Following pulse steroids</td></tr><tr class='med-beers'><td colspan='5' style='background: var(--secondary); color: white; font-weight: 600;'><i class='fas fa-lungs'></i> RESPIRATORY SUPPORT</td></tr><tr><td>Inhalers</td><td>Per usual</td><td>As directed</td><td>Asthma/COPD</td><td>Continue home regimen</td></tr><tr><td>N-Acetylcysteine (NAC)</td><td>600mg</td><td>BID</td><td>Mucolytic</td><td>For bronchiectasis secretion management</td></tr><tr class='med-normal'><td colspan='5' style='background: var(--info); color: white; font-weight: 600;'><i class='fas fa-bacteria'></i> INFECTION TREATMENT</td></tr><tr><td>Antibiotics</td><td>Per culture</td><td>As directed</td><td>Pseudomonas UTI</td><td>Continue until course complete</td></tr>",
        "medCount": "6+",
        "beersCount": "Monitor steroids",
        "ddiCount": "LFT monitoring",
        "medCitation": "Current medication plan Nov 27, 2025"
      }
    },
    {
      "id": "slide-032",
      "type": "geriatric-assessment",
      "order": 31,
      "data": {
        "cogScore": "24",
        "cogInterp": "Baseline intact (per family)",
        "tugScore": "18",
        "tugInterp": "Moderate fall risk (baseline limited by dyspnea)",
        "mnaScore": "9",
        "mnaInterp": "At risk for malnutrition",
        "gdsScore": "Not assessed",
        "gdsInterp": "Patient acutely ill",
        "adlScore": "75",
        "adlInterp": "Mild dependence (limited by respiratory status)",
        "iadlScore": "5",
        "iadlInterp": "Needs assistance with shopping, transport"
      }
    },
    {
      "id": "slide-032b",
      "type": "risk-factors",
      "order": 32,
      "data": {
        "modifiable": "<ul><li><strong>Infection control:</strong> Respiratory infection was the trigger</li><li><strong>Early treatment:</strong> Higher dose steroids at initial HSP diagnosis</li><li><strong>Monitoring:</strong> Serial creatinine checks after HSP diagnosis</li><li><strong>Antibiotic stewardship:</strong> Avoid nephrotoxic agents</li></ul>",
        "nonModifiable": "<ul><li><strong>Age >60:</strong> Higher risk of renal involvement</li><li><strong>Male sex:</strong> Worse renal outcomes in adults</li><li><strong>Underlying CKD:</strong> Even mild baseline impairment</li><li><strong>HBV status:</strong> Complicates treatment options</li></ul>",
        "geriatricRisk": "<ul><li><strong>Polypharmacy:</strong> 8+ medications at baseline</li><li><strong>Frailty:</strong> Chronic respiratory disease</li><li><strong>Reduced renal reserve:</strong> Age-related nephron loss</li><li><strong>Atypical presentations:</strong> Less classic purpura distribution</li><li><strong>Immunosenescence:</strong> Altered immune response</li></ul>",
        "riskStat1": "OR 3.2",
        "riskLabel1": "Age ≥60 for renal HSP",
        "riskStat2": "40-50%",
        "riskLabel2": "Renal involvement in adult HSP",
        "riskStat3": "OR 5.4",
        "riskLabel3": "Proteinuria >1g/d for ESRD"
      }
    },
    {
      "id": "slide-032c",
      "type": "two-column",
      "order": 33,
      "data": {
        "title": "Goals of Care: 78yo with RPGN",
        "leftColumn": "<div class='callout callout-warning'><div class='callout-title'><i class='fas fa-heartbeat'></i> Prognosis</div><div class='callout-content'>Biopsy + Response + HBV</div></div><h4><i class='fas fa-check-circle' style='color:var(--success);'></i> Best Case</h4><ul><li>Active crescents, ↓fibrosis</li><li>Responds to steroids</li><li>Cr stabilizes</li></ul><h4><i class='fas fa-times-circle' style='color:var(--secondary);'></i> Worst Case</h4><ul><li>Fibrosis >50%</li><li>→ Dialysis</li><li>HBV flare</li></ul>",
        "rightColumn": "<div class='callout callout-info'><div class='callout-title'><i class='fas fa-comments'></i> Family Discussion</div></div><h4>1. Treatment Goals</h4><ul><li>Full Tx vs comfort?</li><li>Dialysis: bridge or destination?</li></ul><h4>2. QOL Priorities</h4><ul><li>What matters most?</li><li>Baseline already limited</li></ul><h4>3. Advance Directives</h4><ul><li>Code status?</li><li>Healthcare proxy?</li></ul><div class='callout callout-danger' style='margin-top:8px;'><div class='callout-content'><i class='fas fa-clock'></i> Discuss <strong>NOW</strong></div></div>"
      }
    },
    {
      "id": "slide-032d",
      "type": "section-header",
      "order": 34,
      "data": {
        "sectionTitle": "Teaching Points & Clinical Pearls",
        "sectionNumber": "9"
      }
    },
    {
      "id": "slide-033",
      "type": "teaching-points",
      "order": 35,
      "data": {
        "teachingPoints": "<div class='teaching-point'><div class='teaching-point-number'>1</div><div class='teaching-point-content'><h4>HSP in Elderly = Higher Risk</h4><p>Adult HSP (>65y) → ↑ renal involvement, ↓ prognosis. Screen aggressively!</p></div></div><div class='teaching-point'><div class='teaching-point-number'>2</div><div class='teaching-point-content'><h4>Microhematuria = NEVER Benign</h4><p>In vasculitis, microhematuria warns of RPGN. Early nephro + Cr monitoring.</p></div></div><div class='teaching-point'><div class='teaching-point-number'>3</div><div class='teaching-point-content'><h4>The Dissociation Sign</h4><p>CRP ↓ but Cr ↑ → autoimmune process. Reconsider the diagnosis!</p></div></div><div class='teaching-point'><div class='teaching-point-number'>4</div><div class='teaching-point-content'><h4>Screen HBV Before Steroids</h4><p>Check HBsAg, Anti-HBc, Anti-HBs in ALL patients. Reactivation = fatal.</p></div></div><div class='teaching-point'><div class='teaching-point-number'>5</div><div class='teaching-point-content'><h4>IgA ↑ + ANCA ⊖ = HSP</h4><p>Elevated IgA + negative ANCA/ANA/GBM = IgA Vasculitis (not GPA/MPA).</p></div></div>"
      }
    },
    {
      "id": "slide-034",
      "type": "two-column",
      "order": 36,
      "data": {
        "title": "Prognosis: Awaiting Biopsy",
        "leftColumn": "<h4><i class='fas fa-chart-bar'></i> Biopsy Determines Fate</h4><table class='medications-table'><tbody><tr><td>Mesangial only</td><td style='color:var(--success);'>Excellent</td></tr><tr><td>Focal/segmental</td><td style='color:var(--success);'>Good</td></tr><tr><td>Crescents <50%</td><td style='color:var(--warning);'>Guarded</td></tr><tr><td>Crescents >50%</td><td style='color:var(--secondary);'>Poor</td></tr><tr><td>Fibrosis</td><td style='color:var(--secondary);'>Irreversible</td></tr></tbody></table>",
        "rightColumn": "<h4><i class='fas fa-search'></i> Biopsy Will Show</h4><ul><li>% glomeruli with crescents</li><li>Active vs chronic changes</li><li>IgA deposition pattern</li><li>Tubular/interstitial damage</li></ul><div class='callout callout-info'><div class='callout-content'><strong>Best:</strong> Active crescents, minimal fibrosis<br><strong>Worst:</strong> >50% crescents + fibrosis</div></div>"
      }
    },
    {
      "id": "slide-035",
      "type": "take-home",
      "order": 37,
      "data": {
        "message1": "<strong>RECOGNIZE THE PATTERN</strong><br>Purpura + AKI + active sediment = HSP Nephritis, not just UTI!",
        "message2": "<strong>ACT ON WARNING SIGNS</strong><br>Microhematuria at HSP dx → early nephro referral",
        "message3": "<strong>THE DISSOCIATION SIGN</strong><br>CRP ↓ but Cr ↑ = Autoimmune process. Pivot!",
        "message4": "<strong>SCREEN BEFORE STEROIDS</strong><br>Check HBV status → Entecavir first in HBsAg+ patients",
        "bottomLine": "Infection can trigger devastating autoimmune cascade. RPGN + HBV = complex therapeutic challenge requiring meticulous risk-benefit analysis."
      }
    },
    {
      "id": "slide-036",
      "type": "timeline-visual",
      "order": 38,
      "data": {
        "timelineTitle": "The Five Acts of Mr. Ohayon's Journey",
        "time1": "2018-2025",
        "event1Title": "I: Vulnerable",
        "event1Desc": "Chronic respiratory disease<br>Stable Cr 1.1-1.2",
        "time2": "Oct 2025",
        "event2Title": "II: Trigger",
        "event2Desc": "Infection → Antibiotics<br>→ Purpuric rash",
        "time3": "Oct 29-30",
        "event3Title": "III: Warning",
        "event3Desc": "HSP diagnosed<br>Microhematuria <em>missed</em>",
        "time4": "Nov 20-27",
        "event4Title": "IV-V: Crisis",
        "event4Desc": "AKI, RPGN, HBV+<br>Biopsy done"
      }
    },
    {
      "id": "slide-037",
      "type": "references-formatted",
      "order": 39,
      "data": {
        "references": "<div class='reference-entry'><span class='ref-num'>1.</span><span class='ref-text'>KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2021.</span></div><div class='reference-entry'><span class='ref-num'>2.</span><span class='ref-text'>Pillebout E, et al. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002;13(5):1271-8.</span></div><div class='reference-entry'><span class='ref-num'>3.</span><span class='ref-text'>Audemard-Verger A, et al. IgA vasculitis (Henoch-Shönlein purpura) in adults: Diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579-85.</span></div><div class='reference-entry'><span class='ref-num'>4.</span><span class='ref-text'>Terreri MT, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis. Ann Rheum Dis. 2010;69(5):798-806.</span></div><div class='reference-entry'><span class='ref-num'>5.</span><span class='ref-text'>Perez GO, et al. IgA nephropathy and Henoch-Schönlein purpura nephritis. Semin Nephrol. 2008;28(1):45-55.</span></div><div class='reference-entry'><span class='ref-num'>6.</span><span class='ref-text'>AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology. 2018;67(4):1560-1599.</span></div><div class='reference-entry'><span class='ref-num'>7.</span><span class='ref-text'>Perrillo RP, et al. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology. 2015;148(1):221-244.</span></div><div class='reference-entry'><span class='ref-num'>8.</span><span class='ref-text'>Kitching AR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71.</span></div><div class='reference-entry'><span class='ref-num'>9.</span><span class='ref-text'>Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.</span></div><div class='reference-entry'><span class='ref-num'>10.</span><span class='ref-text'>Patient clinical records, Shaare Zedek Medical Center, October-November 2025.</span></div>"
      }
    },
    {
      "id": "slide-038",
      "type": "key-points-visual",
      "order": 40,
      "data": {
        "kpTitle": "Case Discussion Questions",
        "kp1": "<strong>Q1: Missed workup at HSP Dx?</strong><br><em>A: 24h urine protein, serial Cr, nephro consult</em>",
        "kp2": "<strong>Q2: Key clue UTI→RPGN?</strong><br><em>A: CRP↓ but Cr↑ = \"dissociation sign\"</em>",
        "kp3": "<strong>Q3: Why delay steroids?</strong><br><em>A: HBsAg+ needs Entecavir first (24-48h)</em>",
        "kp4": "<strong>Q4: Why not EGPA?</strong><br><em>A: ANCA⊖, eos suppressed, IgA 651↑↑</em>",
        "kp5": "<strong>Bonus: Eos low?</strong><br><em>A: On Prednisone 20mg - check pre-steroid labs!</em>",
        "kp6": "<strong>Remember:</strong><br><em>When infection improves but kidneys worsen → RPGN</em>"
      }
    },
    {
      "id": "slide-039",
      "type": "two-column",
      "order": 41,
      "data": {
        "title": "What Would You Do?",
        "leftColumn": "<div class='callout callout-warning'><div class='callout-title'><i class='fas fa-flask'></i> Scenario A</div><div class='callout-content'>Biopsy: 60% crescents<br>20% sclerosis, IgA+</div></div><h4>Plan:</h4><ul><li>Prognosis: <strong>Guarded</strong></li><li>Tx: Pulse steroids ± CTX/RTX</li><li>Goals: 50% dialysis risk @2yr</li></ul>",
        "rightColumn": "<div class='callout callout-danger'><div class='callout-title'><i class='fas fa-exclamation-triangle'></i> Scenario B</div><div class='callout-content'>Day 3: Cr 5.2, oliguria<br>K+ 6.1 mEq/L</div></div><h4>Actions:</h4><ul><li><i class='fas fa-phone'></i> Urgent nephro/dialysis</li><li><i class='fas fa-syringe'></i> Treat hyperK (Ca, insulin)</li><li><i class='fas fa-users'></i> Family meeting NOW</li><li><i class='fas fa-pills'></i> Continue steroids</li></ul>"
      }
    },
    {
      "id": "slide-040",
      "type": "timeline-visual",
      "order": 42,
      "data": {
        "timelineTitle": "Lab Trend Summary: The RPGN Trajectory",
        "time1": "Oct 29",
        "event1Title": "HSP Diagnosis",
        "event1Desc": "Cr 1.21, CRP normal, Microhematuria (+)",
        "time2": "Nov 20",
        "event2Title": "Admission",
        "event2Desc": "Cr 2.57 (↑112%), CRP 28.89, Hgb 13.8",
        "time3": "Nov 24",
        "event3Title": "Peak Crisis",
        "event3Desc": "Cr 3.63, CRP 5.24 (↓), Hgb 10.6",
        "time4": "Nov 27",
        "event4Title": "Diagnosis Confirmed",
        "event4Desc": "Cr 3.41, IgA 651, Biopsy done, HBV(+) discovered"
      }
    },
    {
      "id": "slide-041",
      "type": "questions",
      "order": 43,
      "data": {
        "subtitle": "Questions & Discussion",
        "contact": "SZMC Geriatrics Department<br>Case: Eli Ohayon – IgA Vasculitis with RPGN<br><br><em>\"When infection markers improve but kidneys worsen, think beyond the UTI.\"</em>"
      }
    }
  ]
}
